Advantage of serum type-I arginase and ornithine carbamoyltransferase in the evaluation of acute and chronic liver damage induced by thioacetamide in rats

Clinica Chimica Acta

Volumn 375, Issue 1-2, 2007, Pages 63-68

  Murayama, Hiroshi ^a   Ikemoto, Masaki ^b   Fukuda, Yoshihiro ^b   Tsunekawa, Shoji ^c   Nagata, Atsuo ^a  

^a YAMASA CORPORATION   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KANSAI DENRYOKU HOSPITAL   (Japan)

Author keywords

Ornithine carbamoyltransferase; Thioacetamide; Type I arginase

Indexed keywords

ARGINASE; ORNITHINE CARBAMOYLTRANSFERASE; THIOACETAMIDE;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CHRONIC DISEASE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; LIVER CELL; LIVER INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ALANINE TRANSAMINASE; ANIMALS; ARGINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; LIVER; LIVER DISEASES; MALE; ORNITHINE CARBAMOYLTRANSFERASE; RATS; RATS, WISTAR; THIOACETAMIDE;

EID: 33750046015     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.06.018     Document Type: Article

References (23)

1. Sherman K.E. Alanine aminotransferase in clinical practice. Arch Intern Med 151 (1991) 260-265
2. Kronenberger B., Herrmann E., Micol F., von Wagner M., and Zeuzem S. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT activities. Hepatology 40 (2004) 1442-1449
3. Bacon B.R. Treatment of patients with hepatitis C and normal serum aminotransferase activities. Hepatology 36 (2002) S179-S184
4. Mofrad P., Contos M.J., Haque M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003) 1286-1292
5. Wróblewski F., and LaDue J.S. Serum glutamic pyruvic aminotransferase in cardiac with hepatic disease. Proc Soc Exp Biol Med 91 (1956) 569-571
6. Ikemoto M., Tsunekawa S., Awane M., et al. A useful ELISA system for human liver-type arginase, and its utility in diagnosis of liver diseases. Clin Biochem 34 (2001) 455-461
7. Murayama H., Igarashi M., Mori M., Fukuda Y., Ikemoto M., and Nagata A. A sensitive ELISA for serum ornithine carbamoyltransferase utilizing the enhancement of immunoreactivity at alkaline pH. Clin Chim Acta 368 (2006) 125-130
8. Ikemoto M., Ishida A., Tsunekawa S., et al. Enzyme immunoassay of liver-type arginase and its potential clinical application. Clin Chem 39 (1993) 794-799
9. Ikemoto M., Tsunekawa S., Tanaka K., et al. Liver-type arginase in serum during and after liver transplantation: a novel index in monitoring conditions of the liver graft and its clinical significance. Clin Chim Acta 271 (1998) 11-23
10. Ikemoto M., Tsunekawa S., Toda Y., and Totani M. Liver-type arginase is a highly sensitive marker for hepatocellular damage in rats. Clin Chem 47 (2001) 946-948
11. Reichard H. Serum ornithine carbamoyl transferase activity in man. A highly specific test of liver and biliary tract involvement observation on 695 patients. Acta Med Scand 172 (1962) 723-738
12. Oya R., Matsushima T., Kasai M., et al. Clinical meaning of serum ornithine carbamyl transferase (OCT) activity in liver diseases (in Japanese). Sougourinshou 25 (1976) 2250-2254
13. Mehrotra M.P., Pursnani M.L., Singh M.M., and Sharma R.D. Serum ornithine carbamyl transferase (OCT) activity in viral hepatitis. J Assoc Phys India 29 (1981) 457-462
14. Koike T., Hirakawa H., Miyake K., and Tanimizu I. Serum mitochondrial glutamic-oxaloacetic aminotransferase activities in various liver diseases, especially in relation to other biochemical liver function tests (in Japanese). Curr Lab Med 9 (1991) 93-99
15. Watanabe Y., Mori S., Fujiyama S., Sato T., and Mori M. Clinical evaluation of serum ornithine carbamoyltransferase by enzyme-linked immunosorbent assay in patients with liver diseases. Enzyme Protein 48 (1994-1995) 18-26
16. Müller A., Machnik F., Zimmermann T., and Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats-usefulness and reliability of this animal model. Exp Pathol 34 (1988) 229-236
17. Hunter A.L., Holscher M.A., and Neal R.A. Thioacetamide-induced hepatic necrosis. I. Involvement of the mixed-function oxidase enzyme system. J Pharmacol Exp Ther 200 (1977) 439-448
18. Miyanaka K., Gotoh T., Nagasaki A., et al. Immunohistochemical localization of arginase II and other enzymes of arginine metabolism in rat kidney and liver. Histochem J 30 (1998) 741-751
19. Matsuzawa T., Kobayashi T., Ogawa H., and Kasahara M. Microheterogeneity and intrahepatic localization of human and rat liver cytosolic alanine aminotransferase. Biochim Biophys Acta 1340 (1997) 115-122
20. Agius L., and Tosh D. Acinar zonation of cytosolic but not organelle-bound activity of phosphoenolpyruvate carboxykinase and aspartate aminotransferase in guinea-pig liver. Biochem J 271 (1990) 387-391
21. Carakostas M.C., Gossett K.A., Church G.E., and Cleghorn B.L. Evaluating toxin-induced hepatic injury in rats by laboratory results and discriminant analysis. Vet Pathol 23 (1986) 264-269
22. Bondy G.S., Armstrong C.L., Curran I.H.A., Barker M.G., and Mehta R. Retrospective evaluation of serum ornithine carbamyltransferase activity as an index of hepatotoxicity in toxicological studies with rats. Toxicol Lett 114 (2000) 163-171
23. Ohshita M., Takeda H., Kamiyama Y., Ozawa K., and Honjo I. A direct method for the estimation of ornithine carbamoyltransferase activity in serum. Clin Chim Acta 67 (1976) 145-152